Report overview
Gram-negative bacteria are non-pathogenic in person with the normal immune system. However, in person with a weak immune system having gram negative bacteria can behave as significant pathogens. The ability to prevent the effect of such micro-organisms is significantly hampered by the resistance of antimicrobials.
This report contains market size and forecasts of Hospital-Treated Gram-Negative Infections in Global, including the following market information:
Global Hospital-Treated Gram-Negative Infections Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hospital-Treated Gram-Negative Infections market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Klebsiella Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hospital-Treated Gram-Negative Infections include Merck, Pfizer, AstraZeneca, Abbott, Lupin Pharmaceuticals, Istituto lusofarmaco d?italia, Adelco S.A, Zhejiang yuntao biotechnology co., Ltd and Alcon Laboratories. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hospital-Treated Gram-Negative Infections companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hospital-Treated Gram-Negative Infections Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hospital-Treated Gram-Negative Infections Market Segment Percentages, by Type, 2021 (%)
Klebsiella
Acinetobacter
Coli
Cepacia
Pseudomonas
Serratia
Enterobacter
Others
Global Hospital-Treated Gram-Negative Infections Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hospital-Treated Gram-Negative Infections Market Segment Percentages, by Application, 2021 (%)
Public Hospital
Private Hospital
Global Hospital-Treated Gram-Negative Infections Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hospital-Treated Gram-Negative Infections Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hospital-Treated Gram-Negative Infections revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hospital-Treated Gram-Negative Infections revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Pfizer
AstraZeneca
Abbott
Lupin Pharmaceuticals
Istituto lusofarmaco d?italia
Adelco S.A
Zhejiang yuntao biotechnology co., Ltd
Alcon Laboratories
